If you are looking for biotech stocks, you need to keep Zymeworks on your radar right now!
Zymeworks is benefiting significantly from its strategic shift to a revenue-based business model.
Through lucrative partnerships, Zymeworks has a contractual right to future milestone payments of up to $1.5 billion.
Reading Time: 2 minutes
Traders should keep Zymeworks on their radar right now. It is a biopharmaceutical company focused on developing novel, multifunctional antibody therapies for targeted treatment of cancer and other serious diseases. There are several reasons to expect another rise in the stock now: The company presented strong Q4 numbers on March 2. Zymeworks is benefiting significantly from its strategic shift to a revenue-based business model. The annual revenue for 2025 jumped an impressive 176% to $106 million. However, the real leverage lies in the future:...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
